NIR-II fluorescent nanoprobe-labeled lateral flow biosensing platform: A high-performance point-of-care testing for carcinoembryonic antigen
文献类型：期刊论文
| 作者 | Song, Zhaorui1,3; Suo, Yongkuan1,2,3; Duan, Shuang1; Zhang, Shanshan3; Liu, Lifu3; Chen, Botong3; Cheng, Zhen1,3 |
| 刊名 | BIOSENSORS & BIOELECTRONICS
 |
| 出版日期 | 2023-03-15 |
| 卷号 | 224页码:8 |
| 关键词 | Point-of-care testing Immunoassay Rare earth doped nanoparticles NIR-II Carcinoembryonic antigen |
| ISSN号 | 0956-5663 |
| DOI | 10.1016/j.bios.2023.115063 |
| 通讯作者 | Cheng, Zhen(zcheng@simm.ac.cn) |
| 英文摘要 | Fluorescent lateral flow immunoassay (LFA) is one of the most common analytical platforms for point-of-care testing (POCT), which is capable of facile and early screening of biomarkers. Notably, fluorescent probes play a decisive role in analytical performances of LFA. Herein, we report a novel LFA based on the rare earth doped nanoparticles (RENPs) emitting in the second near-infrared (NIR-II) window for the detection of biomarkers, such as carcinoembryonic antigen (CEA). Benefiting from the dual fluorescent emission at NIR-II window, strong fluorescent penetration, low autofluorescence and excellent photostability of RENPs, this proposed NIR-II LFA displays a good linear relationship ranging from 1 to 320 ng mL-1. The detection limit is as low as 0.37 ng mL-1, which is of 13.5 times lower than the clinical cutoff value. Overall, NIR-II LFA biosensing platform based RENPs not only exhibits high sensitivity, accuracy and specificity, but also have characteristics of rapidity, simplicity and low cost. It holds high potential for early diagnosis of tumor biomarkers in POCT. |
| WOS关键词 | ASSAY |
| 资助项目 | Bohai Rim Advanced Research Institute for Drug Discovery ; Natural Science Foundation of Shandong Province[LX215002] ; [ZR2022QH212] |
| WOS研究方向 | Biophysics ; Biotechnology & Applied Microbiology ; Chemistry ; Electrochemistry ; Science & Technology - Other Topics |
| 语种 | 英语 |
| WOS记录号 | WOS:001069569200001 |
| 出版者 | ELSEVIER ADVANCED TECHNOLOGY |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/307149]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Cheng, Zhen |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Mol Imaging Ctr, State Key Lab Drug Res, Shanghai 201203, Peoples R China 2.Northeastern Univ, Inst Mol Med Joint Lab Mol Med, Shenyang 110000, Liaoning, Peoples R China 3.Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, Yantai 264117, Shandong, Peoples R China |
| 推荐引用方式 GB/T 7714 | Song, Zhaorui,Suo, Yongkuan,Duan, Shuang,et al. NIR-II fluorescent nanoprobe-labeled lateral flow biosensing platform: A high-performance point-of-care testing for carcinoembryonic antigen[J]. BIOSENSORS & BIOELECTRONICS,2023,224:8. |
| APA | Song, Zhaorui.,Suo, Yongkuan.,Duan, Shuang.,Zhang, Shanshan.,Liu, Lifu.,...&Cheng, Zhen.(2023).NIR-II fluorescent nanoprobe-labeled lateral flow biosensing platform: A high-performance point-of-care testing for carcinoembryonic antigen.BIOSENSORS & BIOELECTRONICS,224,8. |
| MLA | Song, Zhaorui,et al."NIR-II fluorescent nanoprobe-labeled lateral flow biosensing platform: A high-performance point-of-care testing for carcinoembryonic antigen".BIOSENSORS & BIOELECTRONICS 224(2023):8. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。